Get started

Stockstotrade

TSVT – A Bullish Breakout To MonitorNASDAQ:TSVT is having a nice bullish rally from $1.53 in Nov. 2023 to $5+ price levels. TSVT has reached a key light blue resistance line, and there has been resistance suppressing the price here. However, I am seeing some bullish signs into resistance, and there is the potential for a bullish breakout here. I think it is worth monitoring TSVT for a breakout. I would buy after a confirmed breakout, and the red lines are my key price targets on the way up.
NASDAQ:TSVT
by realchartchamp
2
ADTN 680%+ Long-Term Trade With Risks to ConsiderADTN is approaching my buy zone between $4.79 and $5.13 near historic lows. There are four key price targets on the way up, and the highest price target gives a potential ROI of around 680% if ADTN is able to return back to previous all time highs. There are some financial risks and concerns surrounding ADTN so I recommend reading articles to better understand the situation. Entry Price: $4.79 to $5.13 Sell Targets: - $7.48 - $13.71 - $24.90 - $37.46 Stop Loss: $4.65 I do recommend a stop loss given the financial concerns for ADTN.
NASDAQ:ADTNLong
by realchartchamp
SBLK 200%+ ROI Trade Setup from Insiders in CongressNASDAQ:SBLK is gaining some attention today because Senator Tuberville has purchased $100k worth of SBLK stock, a stock that is focused on forestry and mineral shipping. Senator Tuberville sits on the Senate Committee of Forestry and Agriculture so he could have some insider knowledge here. Buy price: $23 to $24 (I think an entry at $23 is possible, but I wouldn't mind buying at $24). Sell targets: - $77.50 - Previous all time highs are around $1,100. Stop Loss: $22.50, if stopped out the re-entry price is around $16-17. For now let's see if SBLK can get to $77.50 then we can discuss the other targets.
NASDAQ:SBLKLong
by realchartchamp
Cross-Checking News Trading with Technicals on CARR-USDDear Esteemed Investors, Everyone asked me to write an analytics on CARR. Although my forecasts achieved some success with this stock, let me remind you it's only a very small percentage of my portfolio. I can measure my exposure in hundreds of thousands, which is relatively small compared to my gold exposure, which I measure in millions. With that, I care about every one of my investments, and I hear your expectation to read analytics about this stock. Here you go. Chart and Technical Indicators CARR hit the target level of the last bullish forecast ($59.21 resistance), and technical indicators like MACD and RSI turned bearish. Under the chart, MACD shows bearish progress. Both MACD and RSI have a bearish cross on them. These are typical confirmations of resistance, and CARR hasn't defeated it yet. However, RSI still moves on the more bullish side of its chart, and MACD shows only a slight bearishness. It's not too late for CARR investors to continue the rally. Signs of continuation would be if RSI made a bullish cross again and MACD turned bullish. If they can break the mentioned resistance, a target of $61.12 is possible. With that said, the risk-reward ratio of a long isn't excellent here. So, I've taken profit of my long position from the last forecast. I estimate to open a new long if the price confirms support again around the $51.74 level. Breaking this support would suggest a downward trend rather than a healthy retracement. Downwards, the price can fall to lower trendlines below $48. If I open a new long, I'll use a tight stop loss setting. News Trading: AI Natural Language Processing Carrier Global has consistently delivered strong revenue growth in recent quarters, driven by higher demand for HVAC and refrigeration products. The company's recent acquisitions of Viessmann Climate Solutions and Honeywell's Global Access Solutions business expand its market reach and product portfolio. Carrier Global has a healthy balance sheet with a solid financial position. The company has the flexibility to invest in growth initiatives. The global HVAC and refrigeration markets can steadily in the coming years, driven by population growth, urbanization, and rising environmental concerns. On the other hand, the ongoing supply chain disruptions have impacted Carrier Global's production and delivery of products, potentially affecting sales and profitability. Escalating inflation could put downward pressure on consumer spending on discretionary items such as HVAC and refrigeration products. The HVAC and refrigeration industry is highly competitive, with several players vying for market share. The ongoing geopolitical tensions and potential for global recession could dampen demand for Carrier Global's products. Despite the potential headwinds, Carrier Global remains a well-positioned company with a strong track record of growth. The company's focus on innovation, strategic acquisitions, and expanding market reach should support its long-term growth prospects. However, investors should carefully monitor the company's ability to manage supply chain disruptions, inflation, and competitive pressures. Disclaimer: The success of my historic forecasts don't guarantee your future results. It's not an investment advice. Do your esearch. I wrote the analytics for entertainment purposes. Kind regards, Ely
NYSE:CARRLong
by Elysian_Mind
4
SciPlay | SCPLIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in SciPlay. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation especially if its growing. If a company can keep growing earnings per share long enough, its share price should eventually follow. That makes EPS growth an attractive quality for any company. We can see that in the last three years SciPlay grew its EPS by 13% per year. That's a good rate of growth, if it can be sustained. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While SciPlay did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead. You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for SciPlay's future profits. It's a good habit to check into a company's remuneration policies to ensure that the CEO and management team aren't putting their own interests before that of the shareholder with excessive salary packages. Our analysis has discovered that the median total compensation for the CEOs of companies like SciPlay with market caps between US$2.0b and US$6.4b is about US$6.7m. The CEO of SciPlay only received US$3.3m in total compensation for the year ending December 2022. That's clearly well below average, so at a glance that arrangement seems generous to shareholders and points to a modest remuneration culture. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of good governance, more generally. One important encouraging feature of SciPlay is that it is growing profits. To add to this, the modest CEO compensation should tell investors that the directors have an active interest in delivering the best for shareholders. So based on its merits, the stock deserves further research, if not an addition to your watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if SciPlay is trading on a high P/E or a low P/E, relative to its industry. Shares of SciPlay Corp. rose after the company agreed to be acquired by Light & Wonder. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features or you can count on our experts.
SLong
by moonypto
CANO Cano Health Potential Buyout!CANO Cano Health was trading at all time low last friday, $0.22! Last year, I remember that following numerous reports suggesting a potential bid, Citigroup analysts have stated that if Humana or CVS Health were to acquire the primary-care provider Cano Health, they might value it at $14 per share. With $2.74 Billions in revenue in 2022, I think Cano Health is too big to go bankrupt. This might be an interesting buy opportunity, in my opinion!
CLong
by TopgOptions
1
Unveiling the Potential of Pfizer Pharmaceutical Stock in 2023Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust financial performance, join us as we explore why Pfizer is poised to be a game-changer in the pharmaceutical industry and how you can reap substantial rewards by including it in your investment portfolio. Don’t miss out on this exclusive insight into what could be your most profitable venture yet! Monthly price action is supporting a strong bullish correction in the following months. Pfizer is one of the world’s leading pharmaceutical companies and was at the forefront of developing a vaccine for Covid-19 in 2020. The stock price reflected the impact of the vaccine until December 2021, when the stock plunged, losing almost 50% of its value. It’s then when a longer-term demand imbalance takes control and helps us make a high-probability decision to buy and hold shares of Pfizer PFE stock.
NYSE:PFE
by AlfonsoMoreno